FDA warned Great Lakes Gelatin that its collagen products were promoted as unapproved drugs for disease treatment.
What happened
FDA reviewed the company’s website in March–May 2021, along with its Facebook, Pinterest, and YouTube pages, and found product claims and testimonials that Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus treat or prevent disease. FDA said the claims include reduced joint pain, osteoporosis and osteoarthritis treatment or prevention, gastrointestinal healing, and ulcer prevention. The letter also cited scientific publications used on the website as evidence of intended drug use.
What FDA found
FDA said the website claims and testimonials made the collagen products drugs because they were intended to cure, mitigate, treat, or prevent disease.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]FDA said the products are new drugs because they are not generally recognized as safe and effective for the claimed uses and have no FDA approval.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]FDA said the products are misbranded because they lack adequate directions for use for diseases that laypeople cannot safely diagnose or treat without a licensed practitioner.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FDA said scientific publication citations on the website can be evidence of intended disease treatment or prevention when used commercially in labeling.
21 CFR 101.93(g)(2)(iv)(C)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the letter of specific steps taken to address the violations and prevent recurrence, with related documentation. If the company believes there is no violation, it must include its reasoning and supporting information.
Who should pay attention
- dietary supplement brands selling collagen products
- companies that use customer testimonials or scientific citations in product marketing
- regulatory and marketing teams reviewing website and social media claims
This is a summary. Read the original letter on fda.gov.